Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2019, Article ID 7219297, 11 pages
https://doi.org/10.1155/2019/7219297
Review Article

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Sidra Medicine, Member of Qatar Foundation, Doha, Qatar

Correspondence should be addressed to Bella S. Guerrouahen; gro.ardis@nehauorreugb

Received 31 January 2019; Accepted 13 May 2019; Published 5 August 2019

Guest Editor: Marcela F. Bolontrade

Copyright © 2019 Bella S. Guerrouahen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The publication of this article was funded by Qatar National Library.

Linked References

  1. X. Wei, X. Yang, Z. P. Han, F. F. Qu, L. Shao, and Y. F. Shi, “Mesenchymal stem cells: a new trend for cell therapy,” Acta Pharmacologica Sinica, vol. 34, no. 6, pp. 747–754, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. C. Ciuffreda, G. Malpasso, P. Musarò, V. Turco, and M. Gnecchi, “Protocols for in vitro differentiation of human mesenchymal stem cells into osteogenic, chondrogenic and adipogenic lineages,” in Mesenchymal Stem Cells, M. Gnecchi, Ed., vol. 1416 of Methods in Molecular Biology, pp. 149–158, Humana Press, New York, NY, USA, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. E. M. Horwitz, K. le Blanc, M. Dominici et al., “Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement,” Cytotherapy, vol. 7, no. 5, pp. 393–395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Deola, B. S. Guerrouahen, H. Sidahmed et al., “Tailoring cells for clinical needs: meeting report from the advanced therapy in healthcare symposium (October 28–29 2017, Doha, Qatar),” Journal of Translational Medicine, vol. 16, no. 1, article 276, 2018. View at Publisher · View at Google Scholar · View at Scopus
  5. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. L. A. Marquez-Curtis, A. Janowska-Wieczorek, L. E. McGann, and J. A. W. Elliott, “Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects,” Cryobiology, vol. 71, no. 2, pp. 181–197, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Hass, C. Kasper, S. Böhm, and R. Jacobs, “Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC,” Cell Communication and Signaling, vol. 9, no. 1, article 12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Dominici, K. le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Ankrum, J. F. Ong, and J. M. Karp, “Mesenchymal stem cells: immune evasive, not immune privileged,” Nature Biotechnology, vol. 32, no. 3, pp. 252–260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Le Blanc, I. Rasmusson, B. Sundberg et al., “Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells,” The Lancet, vol. 363, no. 9419, pp. 1439–1441, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Le Blanc, F. Frassoni, L. Ball et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” The Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Jitschin, D. Mougiakakos, L. Von Bahr et al., “Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation,” Stem Cells, vol. 31, no. 8, pp. 1715–1725, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Chen, Y. Gan, W. Li et al., “The interaction between mesenchymal stem cells and steroids during inflammation,” Cell Death & Disease, vol. 5, no. 1, article e1009, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Galipeau, M. Krampera, J. Barrett et al., “International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials,” Cytotherapy, vol. 18, no. 2, pp. 151–159, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bartholomew, C. Sturgeon, M. Siatskas et al., “Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo,” Experimental Hematology, vol. 30, no. 1, pp. 42–48, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. A. I. Caplan, “What's in a name?” Tissue Engineering. Part A, vol. 16, no. 8, pp. 2415–2417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. I. Caplan and D. Correa, “The MSC: an injury drugstore,” Cell Stem Cell, vol. 9, no. 1, pp. 11–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. J. Prockop and J. Youn Oh, “Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation,” Molecular Therapy, vol. 20, no. 1, pp. 14–20, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Keating, “Mesenchymal stromal cells: new directions,” Cell Stem Cell, vol. 10, no. 6, pp. 709–716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Wang, Q. Yuan, and L. Xie, “Mesenchymal stem cell-based immunomodulation: properties and clinical application,” Stem Cells International, vol. 2018, Article ID 3057624, 12 pages, 2018. View at Publisher · View at Google Scholar · View at Scopus
  21. M. E. Bernardo and W. E. Fibbe, “Mesenchymal stromal cells: sensors and switchers of inflammation,” Cell Stem Cell, vol. 13, no. 4, pp. 392–402, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Wang, X. Chen, W. Cao, and Y. Shi, “Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications,” Nature Immunology, vol. 15, no. 11, pp. 1009–1016, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Lin and L. Du, “The role of secreted factors in stem cells-mediated immune regulation,” Cellular Immunology, vol. 326, pp. 24–32, 2018. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Dimeloe, A. V. Burgener, J. Grählert, and C. Hess, “T-cell metabolism governing activation, proliferation and differentiation; a modular view,” Immunology, vol. 150, no. 1, pp. 35–44, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Zhuang, Z. Shan, T. Ma et al., “CXCL9 and CXCL10 accelerate acute transplant rejection mediated by alloreactive memory T cells in a mouse retransplantation model,” Experimental and Therapeutic Medicine, vol. 8, no. 1, pp. 237–242, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Keating, “How do mesenchymal stromal cells suppress T cells?” Cell Stem Cell, vol. 2, no. 2, pp. 106–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Su, X. Chen, Y. Huang et al., “Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species,” Cell Death and Differentiation, vol. 21, no. 3, pp. 388–396, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Sato, K. Ozaki, I. Oh et al., “Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells,” Blood, vol. 109, no. 1, pp. 228–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Gieseke, J. Bohringer, R. Bussolari, M. Dominici, R. Handgretinger, and I. Muller, “Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells,” Blood, vol. 116, no. 19, pp. 3770–3779, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Qu, X. Liu, K. Cheng, R. Yang, and R. C. H. Zhao, “Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion,” Experimental Hematology, vol. 40, no. 9, pp. 761–770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Ghannam, J. Pène, G. Torcy-Moquet, C. Jorgensen, and H. Yssel, “Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype,” Journal of Immunology, vol. 185, no. 1, pp. 302–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Wang, S. Huang, X. Yuan et al., “The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus,” Cellular & Molecular Immunology, vol. 14, no. 5, pp. 423–431, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Baratelli, Y. Lin, L. Zhu et al., “Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells,” The Journal of Immunology, vol. 175, no. 3, pp. 1483–1490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Del Papa, P. Sportoletti, D. Cecchini et al., “Notch1 modulates mesenchymal stem cells mediated regulatory T‐cell induction,” European Journal of Immunology, vol. 43, no. 1, pp. 182–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Selmani, A. Naji, I. Zidi et al., “Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells,” Stem Cells, vol. 26, no. 1, pp. 212–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Luk, L. Carreras-Planella, S. S. Korevaar et al., “Inflammatory conditions dictate the effect of mesenchymal stem or stromal cells on B cell function,” Frontiers in Immunology, vol. 8, p. 1042, 2017. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Corcione, F. Benvenuto, E. Ferretti et al., “Human mesenchymal stem cells modulate B-cell functions,” Blood, vol. 107, no. 1, pp. 367–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Franquesa, F. K. Mensah, R. Huizinga et al., “Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells,” Stem Cells, vol. 33, no. 3, pp. 880–891, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Wang, F. Qi, X. Dai et al., “Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin,” Transplant Immunology, vol. 31, no. 2, pp. 65–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Fan, C. Hu, J. Chen, P. Cen, J. Wang, and L. Li, “Interaction between mesenchymal stem cells and B-cells,” International Journal of Molecular Sciences, vol. 17, no. 5, p. 650, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of natural killer cells,” Nature Immunology, vol. 9, no. 5, pp. 503–510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation,” Blood, vol. 107, no. 4, pp. 1484–1490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2,” Blood, vol. 111, no. 3, pp. 1327–1333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. W. G. Watson, “Redox regulation of neutrophil apoptosis,” Antioxidants & Redox Signaling, vol. 4, no. 1, pp. 97–104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Raffaghello, G. Bianchi, M. Bertolotto et al., “Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche,” Stem Cells, vol. 26, no. 1, pp. 151–162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Jiang, J. Muschhammer, Y. Qi et al., “Suppression of neutrophil-mediated tissue damage—a novel skill of mesenchymal stem cells,” Stem Cells, vol. 34, no. 9, pp. 2393–2406, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. A. B. Vasandan, S. Jahnavi, C. Shashank, P. Prasad, A. Kumar, and S. J. Prasanna, “Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism,” Scientific Reports, vol. 6, no. 1, article 38308, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Chiossone, R. Conte, G. M. Spaggiari et al., “Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses,” Stem Cells, vol. 34, no. 7, pp. 1909–1921, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Manferdini, F. Paolella, E. Gabusi et al., “Adipose stromal cells mediated switching of the pro-inflammatory profile of M1-like macrophages is facilitated by PGE2: in vitro evaluation,” Osteoarthritis and Cartilage, vol. 25, no. 7, pp. 1161–1171, 2017. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Kim and P. Hematti, “Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages,” Experimental Hematology, vol. 37, no. 12, pp. 1445–1453, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Magatti, E. Vertua, S. De Munari et al., “Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features,” Journal of Tissue Engineering and Regenerative Medicine, vol. 11, no. 10, pp. 2895–2911, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Lo Sicco, D. Reverberi, C. Balbi et al., “Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization,” Stem Cells Translational Medicine, vol. 6, no. 3, pp. 1018–1028, 2017. View at Publisher · View at Google Scholar · View at Scopus
  53. T. J. Morrison, M. V. Jackson, E. K. Cunningham et al., “Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer,” American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 10, pp. 1275–1286, 2017. View at Publisher · View at Google Scholar · View at Scopus
  54. G. M. Spaggiari and L. Moretta, “Interactions between mesenchymal stem cells and dendritic cells,” in Mesenchymal Stem Cells - Basics and Clinical Application II, B. Weyand, M. Dominici, R. Hass, R. Jacobs, and C. Kasper, Eds., vol. 130 of Advances in Biochemical Engineering/Biotechnology, pp. 199–208, Springer, Berlin, Heidelberg, 2012. View at Publisher · View at Google Scholar
  55. G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta, “MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2,” Blood, vol. 113, no. 26, pp. 6576–6583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Zhang, R. Liu, D. Shi et al., “Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population,” Blood, vol. 113, no. 1, pp. 46–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Krampera, J. Galipeau, Y. Shi, K. Tarte, and L. Sensebe, “Immunological characterization of multipotent mesenchymal stromal cells--the International Society for Cellular Therapy (ISCT) working proposal,” Cytotherapy, vol. 15, no. 9, pp. 1054–1061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Krampera, “Mesenchymal stromal cell ‘licensing’: a multistep process,” Leukemia, vol. 25, no. 9, pp. 1408–1414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. J. R. Ferreira, G. Q. Teixeira, S. G. Santos, M. A. Barbosa, G. Almeida-Porada, and R. M. Gonçalves, “Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning,” Frontiers in Immunology, vol. 9, p. 2837, 2018. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Hu and L. Li, “Preconditioning influences mesenchymal stem cell properties in vitro and in vivo,” Journal of Cellular and Molecular Medicine, vol. 22, no. 3, pp. 1428–1442, 2018. View at Publisher · View at Google Scholar · View at Scopus
  61. L. H. A. Silva, M. A. Antunes, C. C. Dos Santos, D. J. Weiss, F. F. Cruz, and P. R. M. Rocco, “Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases,” Stem Cell Research & Therapy, vol. 9, no. 1, article 45, 2018. View at Publisher · View at Google Scholar · View at Scopus
  62. M. W. Klinker, R. A. Marklein, J. L. Lo Surdo, C. H. Wei, and S. R. Bauer, “Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 13, pp. E2598–E2607, 2017. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Succar, M. Medynskyj, E. J. Breen, T. Batterham, M. P. Molloy, and B. R. Herbert, “Priming adipose-derived mesenchymal stem cells with hyaluronan alters growth kinetics and increases attachment to articular cartilage,” Stem Cells International, vol. 2016, Article ID 9364213, 13 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. E. E. Saether, C. S. Chamberlain, E. Aktas, E. M. Leiferman, S. L. Brickson, and R. Vanderby, “Primed mesenchymal stem cells alter and improve rat medial collateral ligament healing,” Stem Cell Reviews, vol. 12, no. 1, pp. 42–53, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. D. S. Kim, I. K. Jang, M. W. Lee et al., “Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ,” EBioMedicine, vol. 28, pp. 261–273, 2018. View at Publisher · View at Google Scholar · View at Scopus
  66. A. J. Guess, B. Daneault, R. Wang et al., “Safety profile of good manufacturing practice manufactured interferon γ-primed mesenchymal stem/stromal cells for clinical trials,” Stem Cells Translational Medicine, vol. 6, no. 10, pp. 1868–1879, 2017. View at Publisher · View at Google Scholar · View at Scopus
  67. Q. Wang, Q. Yang, Z. Wang et al., “Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton’s jelly as sources of cell immunomodulatory therapy,” Human Vaccines & Immunotherapeutics, vol. 12, no. 1, pp. 85–96, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. J. H. Kim, C. H. Jo, H. R. Kim, and Y. I. Hwang, “Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue,” Stem Cells International, vol. 2018, Article ID 8429042, 12 pages, 2018. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Mendicino, A. M. Bailey, K. Wonnacott, R. K. Puri, and S. R. Bauer, “MSC-based product characterization for clinical trials: an FDA perspective,” Cell Stem Cell, vol. 14, no. 2, pp. 141–145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. H. M. Lazarus, S. E. Haynesworth, S. L. Gerson, N. S. Rosenthal, and A. I. Caplan, “Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use,” Bone Marrow Transplantation, vol. 16, no. 4, pp. 557–564, 1995. View at Google Scholar
  71. O. N. Koç, S. L. Gerson, B. W. Cooper et al., “Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy,” Journal of Clinical Oncology, vol. 18, no. 2, pp. 307–316, 2000. View at Publisher · View at Google Scholar
  72. K. H. Yoo, I. K. Jang, M. W. Lee et al., “Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues,” Cellular Immunology, vol. 259, no. 2, pp. 150–156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. S. M. Melief, J. J. Zwaginga, W. E. Fibbe, and H. Roelofs, “Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts,” Stem Cells Translational Medicine, vol. 2, no. 6, pp. 455–463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. C. de Wolf, M. van de Bovenkamp, and M. Hoefnagel, “Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy,” Cytotherapy, vol. 19, no. 7, pp. 784–797, 2017. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Ancans, “Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development,” Frontiers in Immunology, vol. 3, p. 253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Algeri, A. Conforti, A. Pitisci et al., “Mesenchymal stromal cells and chronic inflammatory bowel disease,” Immunology Letters, vol. 168, no. 2, pp. 191–200, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Serena, N. Keiran, A. Madeira et al., “Crohn’s disease disturbs the immune properties of human adipose-derived stem cells related to inflammasome activation,” Stem Cell Reports, vol. 9, no. 4, pp. 1109–1123, 2017. View at Publisher · View at Google Scholar · View at Scopus
  78. L. B. Lazebnik, A. G. Konopliannikov, O. V. Kniazev et al., “Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases,” Terapevticheskiĭ Arkhiv, vol. 82, no. 2, pp. 38–43, 2010. View at Google Scholar
  79. A. I. Pfizer, “A study to investigate the safety and possible clinical benefit of Multistem(r) in patients with moderate to severe ulcerative colitis,” 2014, https://clinicaltrials.gov/ct2/show/NCT01240915. View at Google Scholar
  80. R. Ciccocioppo, M. E. Bernardo, A. Sgarella et al., “Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease,” Gut, vol. 60, no. 6, pp. 788–798, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Panés, D. García-Olmo, G. van Assche et al., “Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial,” The Lancet, vol. 388, no. 10051, pp. 1281–1290, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. F. de la Portilla, F. Alba, D. García-Olmo, J. M. Herrerías, F. X. González, and A. Galindo, “Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial,” International Journal of Colorectal Disease, vol. 28, no. 3, pp. 313–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Sheridan, “First off-the-shelf mesenchymal stem cell therapy nears European approval,” Nature Biotechnology, vol. 36, no. 3, pp. 212–214, 2018. View at Publisher · View at Google Scholar · View at Scopus
  84. N. Dunavin, A. Dias, M. Li, and J. McGuirk, “Mesenchymal stromal cells: what is the mechanism in acute graft-versus-host disease?” Biomedicines, vol. 5, no. 4, p. 39, 2017. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Galipeau, “The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?” Cytotherapy, vol. 15, no. 1, pp. 2–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Galipeau, “Concerns arising from MSC retrieval from cryostorage and effect on immune suppressive function and pharmaceutical usage in clinical trials,” ISBT Science Series, vol. 8, no. 1, pp. 100-101, 2013. View at Publisher · View at Google Scholar
  87. G. Moll, J. J. Alm, L. C. Davies et al., “Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?” Stem Cells, vol. 32, no. 9, pp. 2430–2442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Galipeau and L. Sensebe, “Mesenchymal stromal cells: clinical challenges and therapeutic opportunities,” Cell Stem Cell, vol. 22, no. 6, pp. 824–833, 2018. View at Publisher · View at Google Scholar · View at Scopus
  89. O. Ringden, A. Baygan, M. Remberger et al., “Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease,” Stem Cells Translational Medicine, vol. 7, no. 4, pp. 325–331, 2018. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Cras, D. Farge, T. Carmoi, J. J. Lataillade, D. D. Wang, and L. Sun, “Update on mesenchymal stem cell-based therapy in lupus and scleroderma,” Arthritis Research & Therapy, vol. 17, no. 1, article 301, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Tyndall, “Mesenchymal stem cell treatments in rheumatology: a glass half full?” Nature Reviews Rheumatology, vol. 10, no. 2, pp. 117–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Tyndall, “Mesenchymal stromal cells and rheumatic disorders,” Immunology Letters, vol. 168, no. 2, pp. 201–207, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. N. Joyce, G. Annett, L. Wirthlin, S. Olson, G. Bauer, and J. A. Nolta, “Mesenchymal stem cells for the treatment of neurodegenerative disease,” Regenerative Medicine, vol. 5, no. 6, pp. 933–946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. T. K. Ng, V. R. Fortino, D. Pelaez, and H. S. Cheung, “Progress of mesenchymal stem cell therapy for neural and retinal diseases,” World Journal of Stem Cells, vol. 6, no. 2, pp. 111–119, 2014. View at Publisher · View at Google Scholar
  95. T. Gharibi, M. Ahmadi, N. Seyfizadeh, F. Jadidi-Niaragh, and M. Yousefi, “Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis,” Cellular Immunology, vol. 293, no. 2, pp. 113–121, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Wang, L. Wang, X. Cong et al., “Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy,” Stem Cells and Development, vol. 22, no. 24, pp. 3192–3202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. R. H. Lee, M. J. Seo, R. L. Reger et al., “Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17438–17443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Jurewicz, S. Yang, A. Augello et al., “Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes,” Diabetes, vol. 59, no. 12, pp. 3139–3147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. P. O. Carlsson, E. Schwarcz, O. Korsgren, and K. le Blanc, “Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells,” Diabetes, vol. 64, no. 2, pp. 587–592, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. J. A. Perez-Simon, O. Lopez-Villar, E. J. Andreu et al., “Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial,” Haematologica, vol. 96, no. 7, pp. 1072–1076, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Introna, G. Lucchini, E. Dander et al., “Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients,” Biology of Blood and Marrow Transplantation, vol. 20, no. 3, pp. 375–381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. D. Wang, J. Li, Y. Zhang et al., “Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study,” Arthritis Research & Therapy, vol. 16, no. 2, p. R79, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al., “Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis,” Archives of Neurology, vol. 67, no. 10, pp. 1187–1194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Connick, M. Kolappan, R. Patani et al., “The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments,” Trials, vol. 12, no. 1, article 62, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Connick, M. Kolappan, C. Crawley et al., “Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study,” The Lancet Neurology, vol. 11, no. 2, pp. 150–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Dhere, I. Copland, M. Garcia et al., “The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial with three doses,” Alimentary Pharmacology & Therapeutics, vol. 44, no. 5, pp. 471–481, 2016. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Galleu, Y. Riffo-Vasquez, C. Trento et al., “Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation,” Science Translational Medicine, vol. 9, no. 416, article eaam7828, 2017. View at Publisher · View at Google Scholar · View at Scopus
  108. R. H. Lee, A. A. Pulin, M. J. Seo et al., “Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6,” Cell Stem Cell, vol. 5, no. 1, pp. 54–63, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Kurtz, “Mesenchymal stem cell delivery routes and fate,” International Journal of Stem Cells, vol. 1, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. R. T. Maziarz, “Mesenchymal stromal cells: potential roles in graft-versus-host disease prophylaxis and treatment,” Transfusion, vol. 56, no. 4, pp. 9S–14S, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Shi, P. Kirwan, and F. J. Livesey, “Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks,” Nature Protocols, vol. 7, no. 10, pp. 1836–1846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. L. Barkholt, E. Flory, V. Jekerle et al., “Risk of tumorigenicity in mesenchymal stromal cell–based therapies—bridging scientific observations and regulatory viewpoints,” Cytotherapy, vol. 15, no. 7, pp. 753–759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. L. He, F. Zhao, Y. Zheng, Y. Wan, and J. Song, “Loss of interactions between p53 and survivin gene in mesenchymal stem cells after spontaneous transformation in vitro,” The International Journal of Biochemistry & Cell Biology, vol. 75, pp. 74–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  114. G. V. Røsland, A. Svendsen, A. Torsvik et al., “Long-term cultures of bone marrow–derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation,” Cancer Research, vol. 69, no. 13, pp. 5331–5339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. H. Y. Lee and I. S. Hong, “Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential,” Cancer Science, vol. 108, no. 10, pp. 1939–1946, 2017. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Mareschi, I. Ferrero, D. Rustichelli et al., “Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow,” Journal of Cellular Biochemistry, vol. 97, no. 4, pp. 744–754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. B. G. Stultz, K. McGinnis, E. E. Thompson, J. L. Lo Surdo, S. R. Bauer, and D. A. Hursh, “Chromosomal stability of mesenchymal stromal cells during in vitro culture,” Cytotherapy, vol. 18, no. 3, pp. 336–343, 2016. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Tarte, J. Gaillard, J. J. Lataillade et al., “Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation,” Blood, vol. 115, no. 8, pp. 1549–1553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. D. A. Cornélio and S. R. B. de Medeiros, “Genetic evaluation of mesenchymal stem cells,” Revista Brasileira de Hematologia e Hemoterapia, vol. 36, no. 4, pp. 238–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Kidd, E. Spaeth, J. L. Dembinski et al., “Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging,” Stem Cells, vol. 27, no. 10, pp. 2614–2623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. B. M. Beckermann, G. Kallifatidis, A. Groth et al., “VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma,” British Journal of Cancer, vol. 99, no. 4, pp. 622–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. R. S. Waterman, S. L. Henkle, and A. M. Betancourt, “Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis,” PLoS One, vol. 7, no. 9, article e45590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. R. de la Fuente, A. Bernad, J. Garcia-Castro, M. C. Martin, and J. C. Cigudosa, “Retraction: spontaneous human adult stem cell transformation,” Cancer Research, vol. 70, no. 16, article 6682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. A. Torsvik, G. V. Rosland, A. Svendsen et al., “Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter,” Cancer Research, vol. 70, no. 15, pp. 6393–6396, 2010. View at Publisher · View at Google Scholar · View at Scopus